Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status

M. Yu. Fedyanin; Федянин М. Ю.; Kh. Kh.-M. El’snukaeva; Эльснукаева Х. Х.-М.; I. A. Pokataev; Покатаев И. А.; A. A. Tryakin; Трякин А. А.; A. A. Bulanov; Буланов А. А.; O. V. Sekhina; Сехина О. В.; D. A. Chekini; Чекини Д. А.; E. O. Ignatova; Игнатова Е. О.; S. S. Gordeev; Гордеев С. С.; M. D. Budurova; Будурова М. Д.; Z. Mamedli; Мамедли З.; D. V. Podluzhnyy; Подлужный Д. В.; N. A. Kozlov; Козлов Н. А.; S. A. Tyulyandin; Тюляндин С. А.

doi:10.17650/2220-3478-2018-8-1-34-41

Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status

Authors: Fedyanin M.Y.¹, El’snukaeva K.K.¹, Pokataev I.A.¹, Tryakin A.A.¹, Bulanov A.A.¹, Sekhina O.V.¹, Chekini D.A.¹, Ignatova E.O.¹, Gordeev S.S.¹, Budurova M.D.¹, Mamedli Z.¹, Podluzhnyy D.V.¹, Kozlov N.A.¹, Tyulyandin S.A.¹
Affiliations:
1. N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Issue: Vol 8, No 1 (2018)
Pages: 34-41
Section: ORIGINAL REPORTS
Published: 29.05.2018
URL: https://onco-surgery.info/jour/article/view/241
DOI: https://doi.org/10.17650/2220-3478-2018-8-1-34-41
ID: 241

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

Objective: to determine the efficacy of 2 oxaliplatin-based chemotherapy regimens (FOLFOX and XELOX) for metastatic colorectal cancer (CRC) depending on the KRAS mutation status and primary tumor location. Materials and methods. We performed retrospective analysis of the data on patients with metastatic CRC taken from a prospective database. We included patients with known KRAS mutation status that received either FOLFOX or XELOX without targeted drugs. Progression-free survival (PFS) was used as a main criterion in estimating treatment efficacy. Results. The inclusion criteria were met by 157 patients. The FOLFOX regimen was more effective in patients with wild-type KRAS CRC: median PFS was 10 months versus 8 months in the XELOX group (hazard ratio (HR) = 0.7; 95 % confidence interval (CI) 0.4–1.2; р = 0.1). However, we observed no significant differences in median life expectancy between these groups: it was 37 and 38 months respectively (HR = 1.1; 95 % CI 0.6–2.1; p = 0.6). Similar trends were observed in patients bearing KRAS mutations: median PFS in the FOLFOX group was 9 months vs 5 months in the XELOX group (HR = 0.6; 95 % CI 0.3–1.2; р = 0.1; p value by Breslow – Day test = 0.04). No differences in median life expectancy between these groups were observed: 33 and 23 months respectively (HR = 0.8; 95 % CI 0.4–1.6; p = 0.5). Conclusion. We failed to find an association between the KRAS mutation status and response to a particular chemotherapy regimen. We found that patients with metastatic CRC receiving the FOLFOX regimen were more likely to achieve objective responses and demonstrated higher median PFS than patients on the XELOX regimen.

Keywords

colon cancer, KRAS gene mutations, chemotherapy, oxaliplatin

References

Supplementary files

Supplementary Files

Action

1. JATS XML

Download

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Efficacy of first-line oxaliplatin-based chemotherapy regimens depending on the KRAS mutation status

Full Text

Abstract

Keywords

About the authors

References

Supplementary files